Dosing & Uses
Dosage Forms & Strengths
- Initiate at 2.5 mg three/four times daily PO
- Maintenance: 5 mg three times daily PO q6hr while patient is awake; reduce dose to 2.5 mg q6hr
- Not to exceed 15 mg/Day
- 0.25 mg q15-30min x 3 doses PRN in lateral deltoid
- Not to exceed 0.5 mg/4 hr
Preterm Labor (Off-label)
Initiate at 2.5-5 mcg/min IV
Increase gradually as tolerated at 20-30 minute intervals
Typical effective dose ranges between 17.5-30 mcg/min IV; some require doses up to 70-80 mcg/min
Continue infusion for 12 hr following cessation of uterine contractions; not to exceed 48-72 hr
PO use or prolonged IV use not recommended (see Black Box Warnings)
GFR <50 mL/min: reduce dose by 50%
GFR >50mL/min: Dose adjustment not necessary
Dosage Forms & Strengths
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Bad taste in mouth
Increased fetal heart rate
Hypoglycemia in some neonates born to women who received drug during labor
Black Box Warnings
Risk of serious adverse events outweighs potential benefit to pregnant women receiving prlonged treatment with terbutaline injection (ie, >48-72 hr), or acute or prolonged treatment with oral terbutaline
Oral terbutaline should not be used for prevention or any treatment of preterm labor because efficacy has not been established and safety concerns similar to IV administration exist
Death and serious adverse reactions have been reported following prolonged administration of oral or injectable terbutaline to pregnant women
Serious events following prolonged use include tachycardia, transient hyperglycemia, hypokalemia, arrhythmias, pulmonary edema, and myocardial ischemia
Hypersensitivity to sympathomimetics
Use >72 hr in management or prevention of preterm labor
Oral administration in preterm labor
History of seizures
History of cardiac disease, including ischemic heart disease or associated arrhythmias
Paradoxical bronchoconstriction may occur with excessive use
Fatalities reported with excessive use of sympathomimetics
Optimize anti-inflammatory treatment prior to administering terbutaline for asthma therapy
Beta-2 agonists may increase serum glucose; use caution in patients with diabetes mellitus
Use caution in glaucoma, hyperthyroidism, seizure disorders, and hypokalemia
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Distributed into breast milk, but in amounts generally considered insufficient to affect nursing infants (AAP Committee states compatible with nursing)
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Beta adrenergic receptor stimulator causing bronchial/uterine smooth muscle relaxation
Onset: 30-45 min (PO); 6-15 min (SC)
Duration: 90 min-4 hr
Peak plasma time: 30-60 min
Half-life: 11-16 hr
Protein binding: 25%
Metabolism: Partially metabolized in liver, mainly to inactive sulfate conjugate
Excretion: 60% urine unchanged, up to 3% feces via bile; remainder in urine as the conjugate (w/ parenteral admin)
Solution: dilute as required in D5W (available form: 1 mg/mL)
Administration: use infusion pump
Protect inj from light
Do not use if discolored
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs